Actively Recruiting
Platelet-Rich Plasma for Peyronie's Disease
Led by Herlev Hospital · Updated on 2025-08-14
84
Participants Needed
1
Research Sites
153 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this clinical trial is to evaluate the effects of Platelet-Rich Plasma (PRP) intralesional injections in men affected by Peyronie's disease (PD) in the fibrotic phase.
CONDITIONS
Official Title
Platelet-Rich Plasma for Peyronie's Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years or older
- Able to provide written informed consent
- Diagnosed with Peyronie's disease without active pain and no worsening curvature over the past 3 months (fibrotic phase)
- Penile curvature between 30 and 95 degrees
- Clearly palpable penile plaque
You will not qualify if you...
- Erectile dysfunction not responding to on-demand PDE5 inhibitors
- Hourglass malformation
- Severely calcified plaques making injection unfeasible
- Intrapenile plaque
- History of priapism
- History of penile fracture
- Previous treatment for Peyronie's disease with injections or surgery
- Use of antithrombotic therapy with high bleeding risk
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Herlev and Gentofte University Hospital
Herlev, Denmark, 2100
Actively Recruiting
Research Team
M
Mikael Heering, MD, Ph.d. student
CONTACT
M
Mikkel M. Fode, Professor, MD, Ph.d.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here